1. Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development.
- Author
-
Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar, Kholmanskikh Van Criekingen, Olga, Koole, Simone, Thomas, David M., and Gelderblom, Hans
- Subjects
- *
DRUG development , *DILEMMA , *INDIVIDUALIZED medicine , *SPATIAL variation , *POLY(ADP-ribose) polymerase - Abstract
Various tests based on different biomarkers have been developed to identify the best candidates for poly(ADP-ribose) polymerase (PARP)-inhibitor therapy. However, due to the absence of harmonization regarding these complex biomarkers, along with various cutoff points and unknown spatial and temporal variations, it is difficult to define the clinical utility of each test and ensure uniformity in treatment decision-making. Here, we propose measures to align biomarker definitions and minimum analytical performance characteristics for diagnostics to ensure equitable and sustainable access to precision medicine. Various tests based on different biomarkers have been developed to identify the best candidates for poly (ADP-ribose) polymerase (PARP)-inhibitor therapy. However, due to the absence of harmonization regarding these complex biomarkers, along with various cutoff points and unknown spatial and temporal variations, it is difficult to define the clinical utility of each test and ensure uniformity in treatment decision-making. Here, we propose measures to align biomarker definitions and minimum analytical performance characteristics for diagnostics to ensure equitable and sustainable access to precision medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF